James C. Mullen
Chief Executive Officer
Mr. Mullen is the Chief Executive Officer of Patheon. He joined Patheon in 2011 as CEO and has continuously contributed to the company’s growth. Mr. Mullen led Patheon in 2012 as it acquired Banner Pharmacaps, a market leader in softgel capsule technology. As a result, all of Banner’s manufacturing sites were structured under Patheon’s existing CMO business, aligning to the rest of its global network. In 2013, he led Patheon in a $2.6 billion transaction that merged Patheon with DSM Pharmaceutical Products, creating DPx. Mr. Mullen is a member of Patheon’s Executive Committee.
Prior to joining Patheon, from 2003 to 2010 Mr. Mullen served as CEO and President at Biogen Idec Inc., one of the world's largest biotechnology companies. Mr. Mullen was responsible for the merger of Biogen and Idec Pharmaceuticals, serving as CEO and President of Biogen from 2000 to 2002, and Chairman, CEO and President of Biogen until the merger was complete in 2003. Additionally, Mr. Mullen held various operating positions at Biogen prior to becoming CEO, including Vice President, Operations. Mr. Mullen also held several manufacturing and engineering positions at Biogen, and over a nine-year period at SmithKline Beecham.
Mr. Mullen possesses more than 30 years of industry experience, ranging from biotechnology, pharmaceuticals to specialty chemicals, as well as extensive expertise in pharmaceutical and biotech manufacturing, engineering, sales, marketing, mergers and acquisitions. Currently, he serves on the Board of Directors for Perkins Elmer Inc. and as a trustee of The Rivers School. He previously served as Chairman of the Biotechnology Industry Organization. Mr. Mullen holds a Bachelor of Science in chemical engineering from Rensselaer Polytechnic Institute and a Master of Business Administration from Villanova University.
Michel Lagarde joined Patheon as its president in 2016. Lagarde leads the global functions and cross-enterprise operations, reporting to Patheon CEO, James Mullen. Lagarde joined Patheon from JLL Partners, a leading middle market private equity firm with a track record focused on healthcare. For the last eight years, he has been working with several of JLL’s portfolio companies in the healthcare and pharma services sectors as managing director, including Patheon. He served as a member of Patheon’s Board of Directors since 2011.
Lagarde, in his role at JLL, was directly involved with members of Patheon’s executive committee for the last five years transforming the company into a global provider of biopharma development and manufacturing services. Patheon has successfully completed and integrated five strategic acquisitions in the last five years, which has more than doubled the company’s revenues and EBITDA.
Prior to joining JLL, Lagarde served as CEO and CFO of the Domestic Appliances and Personal Care division of Philips Electronics North America. Prior, he served as CFO of Philips Electronics in Indonesia and financial controller of Philips Electronics Hong Kong, where he was responsible for a $1 billion industrial footprint. Lagarde earned a B.B.A from European University Antwerp and an Executive Master in Finance & Control from the University of Maastricht & Amsterdam.
Executive Vice President and Chief Financial Officer
Stuart Grant serves as Executive Vice President and Chief Financial Officer for Patheon having joined the company in 2012. Prior to joining Patheon, he served as Senior Vice President and Chief Financial Officer of BioCryst Pharmaceuticals, Inc., where he was a key player in the creation and execution of a company-wide strategy that stabilized, funded and enabled commercialization activities. Prior to BioCryst, Mr. Grant was Group Chief Financial Officer for Serono SA, Europe's largest biotechnology company. Over 12 years, he served in various senior operating and financial roles, including Finance Director for Swiss Manufacturing Operations and then General Manager of the company's manufacturing laboratories. Mr. Grant also spent 15 years in finance at Digital Equipment Corporation, and several years working as a tax consultant and senior auditor for Price Waterhouse in Glasgow, Scotland. Mr. Grant is a member of Patheon’s Executive Committee.
Eric M. Sherbet
General Counsel and Secretary
Mr. Sherbet possesses more than 25 years of experience representing global public and private equity backed companies in the pharmaceutical, professional services, engineering and construction, and telecommunication sectors. Mr. Sherbet is known for helping companies during periods of rapid growth and serving as a trusted advisor to management and boards of directors. Based in Boston, Mr. Sherbet serves Patheon as General Counsel, overseeing all global legal affairs, corporate compliance and regulatory matters, in addition to his role as secretary of the company’s board of directors. Mr. Sherbet also oversees human resources, compensation & benefits and government affairs. Prior to joining the company’s senior leadership team in 2014, he built the legal and compliance department of inVentiv Health, Inc. to support business concerns, including mergers and acquisitions, SEC filings, compliance and regulatory issues, and commercial deals. Mr. Sherbet earned his Bachelor of Science in commerce from the University of Virginia and a Juris Doctor from the New York University School of Law. Mr. Sherbet is a member of Patheon’s Executive Committee.
Executive Vice President, Corporate Development and Strategy
Michael Lytton is Executive Vice President, Corporate Development and Strategy at Patheon. Mr. Lytton also leads the company's product and technology business, Banner Life Sciences. Prior to Patheon, Mr. Lytton spent three years as Executive Vice President, Corporate and Business Development at Biogen Idec. From 2001 to 2008, Mr. Lytton was General Partner at Oxford Bioscience Partners, a venture capital firm investing in therapeutic, diagnostic and life science companies. He practiced law from 1984 to 2000, specializing in representing biomedical companies. He was a partner and a member of the executive committee at the law firm Edwards Wildman Palmer, and was a partner at the law firm, Wilmer Hale. Mr. Lytton served as Chairman of the Board at Santhera Pharmaceuticals AG from 2004 to 2011, and served on various boards of many other academic, nonprofit, and private and public for-profit companies. Mr. Lytton holds an undergraduate degree from Princeton University, a Master of Science in epidemiology from the London School of Hygiene and Tropical Medicine at the University of London, U.K., where he was a Fulbright Scholar. Additionally, he earned a Juris Doctor from Harvard Law School. Mr. Lytton is a member of Patheon’s Executive Committee.
Rebecca Holland New
Corporate Officer and EVP, Enterprise-wide Operations
Ms. Holland New serves as Corporate Officer and EVP, Enterprise-wide Operations responsible for $1b+ procurement organization, across 27 sites and shipping to 70+ countries. She leads the company project management & integration office including M&A diligence, critical path to close, talent, structure, resource planning and integration. Ms. Holland New is responsible for global business services overseeing strategic vendor relationships for IT, procurement, human resources, and finance. Ms. Holland New is a member of the company’s executive committee and enterprise operations team. Prior to this role, Ms. Holland New served as chief human resources officer and executive vice president of human resources, global integration & growth project management. Prior to joining Patheon she served as global vice president of human resources at Bausch & Lomb. Before becoming global VP, HR at Bausch & Lomb, she held global human resources leadership positions at the company’s business operations, talent, corporate and pharmaceutical business units as well as global research and development. Ms. Holland New earned a master's degree in industrial and labor relations as well as Bachelor of Science degree in economics, marketing and finance from Cornell University. In addition, she completed coursework toward a Ph.D./Master of Science in organizational psychology from Columbia University and Rutgers University.
Chief of Staff
Mr. Shope serves as Chief of Staff at Patheon where he leads the company’s community and government relations initiatives. Previously, he worked as an international business adviser for the Riyadh Technology Valley in Saudi Arabia. Mr. Shope has also served as vice president and officer for the Research Triangle Park Foundation, which owns and operates the internationally recognized Research Triangle Park. In addition, he directed international business development at the North Carolina Department of Commerce, intricately involved with two North Carolina governors. Mr. Shope served as principal of Schottenstein, Zox, & Dunn, a law firm headquartered in Columbus, Ohio. He earned a Master of Public Administration from the University of North Carolina at Chapel Hill, and attended a one-year program at Yale University after graduating from West Virginia Wesleyan College.
President, Drug Product Services
With more than 20 years of experience in the pharmaceutical industry, Mr. Negron joined Patheon in November 2009 as Vice President and General Manager of the company’s operations in Puerto Rico. Prior to joining Patheon, he served in various senior positions, including Global Vice President at Novartis Consumer Health, Over-the-Counter and Pharmaceutical Products with specific focus on global process improvement initiatives. Prior to that, he served as Vice President, Manufacturing and Supply at Valeant Pharmaceuticals and Site General Manager at McNeil Consumer Healthcare. Mr. Negron holds a Bachelor of Science in electrical engineering from the University of Puerto Rico.
Lukas Utiger, Ph.D.
President, Drug Substance
Dr. Utiger is President of the drug substance network at Patheon. Most recently, he served as President and CEO of the DSM Pharmaceutical Products and DPx Fine Chemicals. Before joining DSM in 2013, Dr. Utiger served as Chief Operating Officer of the bioscience division at Lonza Group AG. Prior to that, he served as Chief Operating Officer of the company’s life science ingredients division, Head of the exclusive synthesis business sector, and Head of Research and Development for Exclusive Synthesis. He joined Lonza in 1992 as an R&D Chemist and advanced to Group Leader for fine chemicals in 1998. Dr. Utiger began his career at ICI chemicals & polymers division in 1988. He earned his Ph.D. in chemical engineering at Imperial College, London.
President, Pharmaceutical Development Services
Gilles Cottier serves as president of Patheon’s Pharmaceutical Development Services (PDS) business where he is responsible for leading the company’s formulation development services and full breadth of advanced scientific services from discovery to regulatory approval, analytical services and lifecycle management. Cottier joined Patheon in 2016 from Sigma-Aldrich Corporation where he served as president and executive vice president of the Sigma-Aldrich Fine Chemicals (SAFC) Commercial Unit. At Sigma-Aldrich Cottier was responsible for contract manufacturing and the commercial services business unit which achieved $701 million in sales in 2014. Cottier held numerous positions of increasing responsibility at Sigma-Aldrich during his more than 25 years with the company. He holds a Master’s Degree in Organic Chemistry from the Ecole Supérieure de Chimie Industrielle de Lyon, France and he completed the Advanced Management Program at Harvard Business School in Boston, MA. Cottier is a member of Patheon’s Executive Committee.
President, Global Sales and Marketing
Mr. Lehmann serves as president, global sales and marketing for Patheon. He joined the company in 2012 and previously oversaw global Pharmaceutical Development Services (PDS) as well as global sales and marketing. Prior to joining Patheon, Mr. Lehmann served as Corporate Senior Vice President and General Manager of the Global Early Development business of Covance from 2005 to 2012, which is one of the world’s largest drug development services companies. In that role, he was responsible for global early development and P&L management; his key accomplishments included executive leadership in strategic deals between Covance, Lilly and Sanofi. Prior to joining Covance, Mr. Lehmann worked for 17 years at GE Healthcare in key operational and management roles. His career started with a focus in client services, managing large call centers for both external customers and repair technicians. In 1998, he was tasked with assisting in the integration of the company’s MECON acquisition, operational and clinical performance optimization services. Mr. Lehmann progressed through various other comparable roles to emerge as the General Manager of the Multivendor Solutions business in 2003, where he was responsible for facilitating the upkeep and repair of other OEM diagnostic imaging equipment and accessories with complete P&L responsibilities. Mr. Lehmann holds a Master of Business Administration from Marquette University and a Bachelor of Science in mechanical engineering from the Catholic University of America.
Sr. Vice President, Quality, Operational Excellence & Patheon Way
Mr. Gill serves as Senior Vice President, Quality, Operational Excellence and The Patheon Way. He joined Patheon in 2010 as Global Vice President, Operational Excellence and Vice President, North America Business Management. Mr. Gill drove the development of a core model and tools for assessing Operational Excellence (OE) at Patheon focusing on culture, structure and process. He is leading the Patheon Way, an initiative for standardizing best practices across the company’s global network. He brings more than 25 years of experience in quality, plant operations, technical services and operational excellence, having held various positions at Wyeth (now known as Pfizer Pharmaceuticals) and Baxter Healthcare Corporation. In addition, he has eight years of combined international experience in Asia and Puerto Rico. Mr. Gill received a Bachelor of Science in biology from Milligan College and a Master of Science in microbiology from East Tennessee State University.
Sr. Vice President, Global Capacity Planning and Engineering
Ray Guidotti serves as senior vice president of global capacity planning and engineering for Patheon overseeing the company’s 26 manufacturing sites around the world and the growing needs of the business. He is driving the business process transformation – working to increase efficiency and cost-effectiveness. He joined Patheon in 2009, bringing more than 25 years of experience in engineering, facilities and project management. Mr. Guidotti started his pharmaceuticals career with Bristol-Myers Squibb and since then has held progressively senior technical leadership positions within the industry. Prior to joining Patheon, he spent a number of years in an industry consulting practice, supporting various pharmaceutical clients in the development and execution of network-wide strategy and business change projects. Mr. Guidotti holds a degree in marine engineering from New York Maritime College and is a registered professional engineer.
Laura L. Parks
Sr. Vice President, Enterprise Customers and OneSource™
Dr. Laura Parks is a transformational business leader with record of developing high performance, market-focused teams. She is currently leading cross-business segment key client relationships and Patheon OneSource™. Patheon OneSource™ allows clients to combine drug substance and drug product development and manufacturing into a single customized solution to simplify supply chain management. Prior to her current role, Dr. Parks served as president of DSM Pharmaceuticals where she had full P&L accountability for the finished dose contract manufacturing organization of DSM Pharmaceuticals until its merger with Patheon in March 2014. She also previously served as regional vice president, North America for Solae, a division of DuPont, where she led a $120 million food ingredients business unit. She was vice president of sales for Solae for two years. Dr. Parks earned a Ph.D. in Food Science from the University of Georgia and a Bachelor of Science degree in Animal Science from The Ohio State University.